LKPC(SH:600789)2026-01-27 09:00Financial Projections - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 110 million and 145 million yuan, representing a year-on-year decrease of 63.26% to 72.13%[2] - The net profit excluding non-recurring gains and losses is projected to be between 80 million and 118 million yuan, reflecting a year-on-year decline of 43.43% to 61.65%[3] - The previous year's net profit attributable to shareholders was 394.62 million yuan, with a total profit of 433.90 million yuan[4] Performance Factors - The decrease in performance is primarily due to non-recurring gains from land transfer in the previous year, market demand slowdown, and increased competition[5] R&D Investment - The company is increasing investment in R&D for innovative drugs and high-end formulations, which is expected to impact short-term profits[5]